IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v13y2022i1d10.1038_s41467-022-29442-x.html
   My bibliography  Save this article

Ubiquitin ligase STUB1 destabilizes IFNγ-receptor complex to suppress tumor IFNγ signaling

Author

Listed:
  • Georgi Apriamashvili

    (The Netherlands Cancer Institute)

  • David W. Vredevoogd

    (The Netherlands Cancer Institute)

  • Oscar Krijgsman

    (The Netherlands Cancer Institute)

  • Onno B. Bleijerveld

    (The Netherlands Cancer Institute)

  • Maarten A. Ligtenberg

    (The Netherlands Cancer Institute)

  • Beaunelle Bruijn

    (The Netherlands Cancer Institute)

  • Julia Boshuizen

    (The Netherlands Cancer Institute)

  • Joleen J. H. Traets

    (The Netherlands Cancer Institute)

  • Daniela D’Empaire Altimari

    (The Netherlands Cancer Institute)

  • Alex Vliet

    (The Netherlands Cancer Institute)

  • Chun-Pu Lin

    (The Netherlands Cancer Institute)

  • Nils L. Visser

    (The Netherlands Cancer Institute)

  • James D. Londino

    (The Ohio State University Wexner Medical Center)

  • Rebekah Sanchez-Hodge

    (The University of North Carolina at Chapel Hill)

  • Leah E. Oswalt

    (The University of North Carolina at Chapel Hill)

  • Selin Altinok

    (The University of North Carolina at Chapel Hill)

  • Jonathan C. Schisler

    (The University of North Carolina at Chapel Hill)

  • Maarten Altelaar

    (The Netherlands Cancer Institute
    University of Utrecht, and Netherlands Proteomics Center)

  • Daniel S. Peeper

    (The Netherlands Cancer Institute)

Abstract

The cytokine IFNγ differentially impacts on tumors upon immune checkpoint blockade (ICB). Despite our understanding of downstream signaling events, less is known about regulation of its receptor (IFNγ-R1). With an unbiased genome-wide CRISPR/Cas9 screen for critical regulators of IFNγ-R1 cell surface abundance, we identify STUB1 as an E3 ubiquitin ligase for IFNγ-R1 in complex with its signal-relaying kinase JAK1. STUB1 mediates ubiquitination-dependent proteasomal degradation of IFNγ-R1/JAK1 complex through IFNγ-R1K285 and JAK1K249. Conversely, STUB1 inactivation amplifies IFNγ signaling, sensitizing tumor cells to cytotoxic T cells in vitro. This is corroborated by an anticorrelation between STUB1 expression and IFNγ response in ICB-treated patients. Consistent with the context-dependent effects of IFNγ in vivo, anti-PD-1 response is increased in heterogenous tumors comprising both wildtype and STUB1-deficient cells, but not full STUB1 knockout tumors. These results uncover STUB1 as a critical regulator of IFNγ-R1, and highlight the context-dependency of STUB1-regulated IFNγ signaling for ICB outcome.

Suggested Citation

  • Georgi Apriamashvili & David W. Vredevoogd & Oscar Krijgsman & Onno B. Bleijerveld & Maarten A. Ligtenberg & Beaunelle Bruijn & Julia Boshuizen & Joleen J. H. Traets & Daniela D’Empaire Altimari & Ale, 2022. "Ubiquitin ligase STUB1 destabilizes IFNγ-receptor complex to suppress tumor IFNγ signaling," Nature Communications, Nature, vol. 13(1), pages 1-16, December.
    • Handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-29442-x
    DOI: 10.1038/s41467-022-29442-x
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-022-29442-x
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-022-29442-x?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Markus Brockmann & Vincent A. Blomen & Joppe Nieuwenhuis & Elmer Stickel & Matthijs Raaben & Onno B. Bleijerveld & A. F. Maarten Altelaar & Lucas T. Jae & Thijn R. Brummelkamp, 2017. "Genetic wiring maps of single-cell protein states reveal an off-switch for GPCR signalling," Nature, Nature, vol. 546(7657), pages 307-311, June.
    2. Robert T. Manguso & Hans W. Pope & Margaret D. Zimmer & Flavian D. Brown & Kathleen B. Yates & Brian C. Miller & Natalie B. Collins & Kevin Bi & Martin W. LaFleur & Vikram R. Juneja & Sarah A. Weiss &, 2017. "In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target," Nature, Nature, vol. 547(7664), pages 413-418, July.
    3. Paul C. Tumeh & Christina L. Harview & Jennifer H. Yearley & I. Peter Shintaku & Emma J. M. Taylor & Lidia Robert & Bartosz Chmielowski & Marko Spasic & Gina Henry & Voicu Ciobanu & Alisha N. West & M, 2014. "PD-1 blockade induces responses by inhibiting adaptive immune resistance," Nature, Nature, vol. 515(7528), pages 568-571, November.
    4. Antje Sucker & Fang Zhao & Natalia Pieper & Christina Heeke & Raffaela Maltaner & Nadine Stadtler & Birgit Real & Nicola Bielefeld & Sebastian Howe & Benjamin Weide & Ralf Gutzmer & Jochen Utikal & Ca, 2017. "Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions," Nature Communications, Nature, vol. 8(1), pages 1-15, August.
    5. Juan L. Mendoza & Nichole K. Escalante & Kevin M. Jude & Junel Sotolongo Bellon & Leon Su & Tim M. Horton & Naotaka Tsutsumi & Steven J. Berardinelli & Robert S. Haltiwanger & Jacob Piehler & Edgar G., 2019. "Structure of the IFNγ receptor complex guides design of biased agonists," Nature, Nature, vol. 567(7746), pages 56-60, March.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Dzana Dervovic & Ahmad A. Malik & Edward L. Y. Chen & Masahiro Narimatsu & Nina Adler & Somaieh Afiuni-Zadeh & Dagmar Krenbek & Sebastien Martinez & Ricky Tsai & Jonathan Boucher & Jacob M. Berman & K, 2023. "In vivo CRISPR screens reveal Serpinb9 and Adam2 as regulators of immune therapy response in lung cancer," Nature Communications, Nature, vol. 14(1), pages 1-21, December.
    2. Martin Lauss & Bengt Phung & Troels Holz Borch & Katja Harbst & Kamila Kaminska & Anna Ebbesson & Ingrid Hedenfalk & Joan Yuan & Kari Nielsen & Christian Ingvar & Ana Carneiro & Karolin Isaksson & Kri, 2024. "Molecular patterns of resistance to immune checkpoint blockade in melanoma," Nature Communications, Nature, vol. 15(1), pages 1-14, December.
    3. Mike B. Barnkob & Yale S. Michaels & Violaine André & Philip S. Macklin & Uzi Gileadi & Salvatore Valvo & Margarida Rei & Corinna Kulicke & Ji-Li Chen & Vitul Jain & Victoria K. Woodcock & Huw Colin-Y, 2024. "Semaphorin 3A causes immune suppression by inducing cytoskeletal paralysis in tumour-specific CD8+ T cells," Nature Communications, Nature, vol. 15(1), pages 1-18, December.
    4. Maria Pia Lenza & Leire Egia-Mendikute & Asier Antoñana-Vildosola & Cátia O. Soares & Helena Coelho & Francisco Corzana & Alexandre Bosch & Prodhi Manisha & Jon Imanol Quintana & Iker Oyenarte & Luca , 2023. "Structural insights into Siglec-15 reveal glycosylation dependency for its interaction with T cells through integrin CD11b," Nature Communications, Nature, vol. 14(1), pages 1-14, December.
    5. Jia Wei & Xiaofeng Lu & Qin Liu & Yao Fu & Song Liu & Yang Zhao & Jiawei Zhou & Hui Chen & Meng Wang & Lin Li & Ju Yang & Fangcen Liu & Liming Zheng & Haitao Yin & Yang Yang & Chong Zhou & Ping Zeng &, 2023. "Neoadjuvant sintilimab in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: a single-arm phase 2 trial," Nature Communications, Nature, vol. 14(1), pages 1-12, December.
    6. Xiaofeng Liao & Wenxue Li & Hongyue Zhou & Barani Kumar Rajendran & Ao Li & Jingjing Ren & Yi Luan & David A. Calderwood & Benjamin Turk & Wenwen Tang & Yansheng Liu & Dianqing Wu, 2024. "The CUL5 E3 ligase complex negatively regulates central signaling pathways in CD8+ T cells," Nature Communications, Nature, vol. 15(1), pages 1-20, December.
    7. Chunping Mao & Fuan Deng & Wanning Zhu & Leiming Xie & Yijun Wang & Guoyin Li & Xingke Huang & Jiahui Wang & Yue Song & Ping Zeng & Zhenpeng He & Jingnan Guo & Yao Suo & Yujing Liu & Zhuo Chen & Mingx, 2024. "In situ editing of tumour cell membranes induces aggregation and capture of PD-L1 membrane proteins for enhanced cancer immunotherapy," Nature Communications, Nature, vol. 15(1), pages 1-20, December.
    8. Austin M. Gabel & Andrea E. Belleville & James D. Thomas & Siegen A. McKellar & Taylor R. Nicholas & Toshihiro Banjo & Edie I. Crosse & Robert K. Bradley, 2024. "Multiplexed screening reveals how cancer-specific alternative polyadenylation shapes tumor growth in vivo," Nature Communications, Nature, vol. 15(1), pages 1-14, December.
    9. Ziyang Cao & Dongdong Li & Liang Zhao & Mengting Liu & Pengyue Ma & Yingli Luo & Xianzhu Yang, 2022. "Bioorthogonal in situ assembly of nanomedicines as drug depots for extracellular drug delivery," Nature Communications, Nature, vol. 13(1), pages 1-12, December.
    10. Nina Frey & Luigi Tortola & David Egli & Sharan Janjuha & Tanja Rothgangl & Kim Fabiano Marquart & Franziska Ampenberger & Manfred Kopf & Gerald Schwank, 2022. "Loss of Rnf31 and Vps4b sensitizes pancreatic cancer to T cell-mediated killing," Nature Communications, Nature, vol. 13(1), pages 1-11, December.
    11. Thomas Thisted & F. Donelson Smith & Arnab Mukherjee & Yuliya Kleschenko & Feng Feng & Zhi-Gang Jiang & Timothy Eitas & Kanam Malhotra & Zuzana Biesova & Adejumoke Onumajuru & Faith Finley & Anokhi Ci, 2024. "VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response," Nature Communications, Nature, vol. 15(1), pages 1-16, December.
    12. Elaine Lai-Han Leung & Run-Ze Li & Xing-Xing Fan & Lily Yan Wang & Yan Wang & Zebo Jiang & Jumin Huang & Hu-Dan Pan & Yue Fan & Hongmei Xu & Feng Wang & Haopeng Rui & Piu Wong & Hermi Sumatoh & Michae, 2023. "Longitudinal high-dimensional analysis identifies immune features associating with response to anti-PD-1 immunotherapy," Nature Communications, Nature, vol. 14(1), pages 1-9, December.
    13. Rana Falahat & Anders Berglund & Patricio Perez-Villarroel & Ryan M. Putney & Imene Hamaidi & Sungjune Kim & Shari Pilon-Thomas & Glen N. Barber & James J. Mulé, 2023. "Epigenetic state determines the in vivo efficacy of STING agonist therapy," Nature Communications, Nature, vol. 14(1), pages 1-16, December.
    14. Jani Huuhtanen & Liang Chen & Emmi Jokinen & Henna Kasanen & Tapio Lönnberg & Anna Kreutzman & Katriina Peltola & Micaela Hernberg & Chunlin Wang & Cassian Yee & Harri Lähdesmäki & Mark M. Davis & Sat, 2022. "Evolution and modulation of antigen-specific T cell responses in melanoma patients," Nature Communications, Nature, vol. 13(1), pages 1-14, December.
    15. Anna Gogleva & Dimitris Polychronopoulos & Matthias Pfeifer & Vladimir Poroshin & Michaël Ughetto & Matthew J. Martin & Hannah Thorpe & Aurelie Bornot & Paul D. Smith & Ben Sidders & Jonathan R. Dry &, 2022. "Knowledge graph-based recommendation framework identifies drivers of resistance in EGFR mutant non-small cell lung cancer," Nature Communications, Nature, vol. 13(1), pages 1-14, December.
    16. Tian-mei Zeng & Guang Yang & Cheng Lou & Wei Wei & Chen-jie Tao & Xi-yun Chen & Qin Han & Zhuo Cheng & Pei-pei Shang & Yu-long Dong & He-ming Xu & Lie-ping Guo & Dong-sheng Chen & Yun-jie Song & Chuan, 2023. "Clinical and biomarker analyses of sintilimab plus gemcitabine and cisplatin as first-line treatment for patients with advanced biliary tract cancer," Nature Communications, Nature, vol. 14(1), pages 1-14, December.
    17. Stefanie Hiltbrunner & Lena Cords & Sabrina Kasser & Sandra N. Freiberger & Susanne Kreutzer & Nora C. Toussaint & Linda Grob & Isabelle Opitz & Michael Messerli & Martin Zoche & Alex Soltermann & Mar, 2023. "Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype," Nature Communications, Nature, vol. 14(1), pages 1-14, December.
    18. Irineos Papakyriacou & Ginte Kutkaite & Marta Rúbies Bedós & Divya Nagarajan & Liam P. Alford & Michael P. Menden & Yumeng Mao, 2024. "Loss of NEDD8 in cancer cells causes vulnerability to immune checkpoint blockade in triple-negative breast cancer," Nature Communications, Nature, vol. 15(1), pages 1-19, December.
    19. Maud Rijnders & J. Alberto Nakauma-González & Debbie G. J. Robbrecht & Alberto Gil-Jimenez & Hayri E. Balcioglu & Astrid A. M. Oostvogels & Maureen J. B. Aarts & Joost L. Boormans & Paul Hamberg & Mic, 2024. "Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer," Nature Communications, Nature, vol. 15(1), pages 1-13, December.
    20. Christos Miliotis & Yuling Ma & Xanthi-Lida Katopodi & Dimitra Karagkouni & Eleni Kanata & Kaia Mattioli & Nikolas Kalavros & Yered H. Pita-Juárez & Felipe Batalini & Varune R. Ramnarine & Shivani Nan, 2024. "Determinants of gastric cancer immune escape identified from non-coding immune-landscape quantitative trait loci," Nature Communications, Nature, vol. 15(1), pages 1-15, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-29442-x. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.